Genentech has terminated its collaboration agreement with Seattle Genetics for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma. The decision is a result of Genentech’s ongoing portfolio review process; Genentech and parent company Roche have ended several partnerships and alliances in recent weeks. The effective date of the termination will be 180 days from the date of notific...